Tele No.011-23236965
Fax.No.011-23236973

F. No. ND/MA/25/000147
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-11 0002

To
M/s. Cipla Ltd.,
Cipla House, Peninsula Business Park Ganpatrao Kadam Marg,
Lower Parel, Mumbai, Maharashtra - 400013

Subject: A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate Efficacy, Safety, and Tolerability of Ensifentrine Inhalation Suspension 3mg/2.5mL over 24 weeks in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (Study code: CP/03/25, Version 2.0 dated: 29.12.2025- regarding.

Sir,

With reference to your application no. **ND/CT21/FF/2025/52109 dated 23.09.2025**; please find enclosed herewith the permission in **Form CT-06, vide No. CT/ND/09/2026** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully

RAJEEV SINGH RAGHUVANSHI
Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2026.03.13 17:23:49 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

Conditions of permission

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules.

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier.

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority.

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination.

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be

intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

(xix) The Informed Consent Document including ICF and Patient Information Sheet should clearly mention in understandable language about the details of the drug therapy that the patient may or may not receive.

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG ~~OR INVESTIGATIONAL NEW DRUG~~

CT Permission No. CT/ND/09/2026

The Central Licensing Authority hereby permits **M/s. Cipla Ltd, Cipla House, Peninsula Business Park Ganpatrao Kadam Marg, Lower Parel, Mumbai, Maharashtra-400013, Telephone No.: 91-22-24826000 FAX: 91-22-24826120, E-mail: vipul.gupta2@cipla.com** to conduct clinical trial of the new drug as per **Study code: CP/03/25 Version no. 2.0 dated: 29.12.2025** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

Names of the new drug ~~or investigational new drug:~~		Ensifentrine Inhalation Suspension 3mg (3 mg/2.5ml)
Therapeutic class:		Selective dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) indicated for the maintenance treatment of COPD
Dosage form:		Inhalation Suspension
Composition:		Each 2.5ml unit dose ampoule contains: Ensifentrine - 3mg
Indications:		Indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients
Details of clinical trial sites-		
Sr. No.	**Name of Principal Investigator & Trial Sites**	**Ethics Committee Name/ Registration Number**
1.	**Dr Rohit Kumar** Pulmonary critical care & Sleep Medicine, SSB Building, VMMC & Safdarjung Hospital, New Delhi 110029	Institutional Ethics Committee, VMMC & Safdarjung Hospital, Room No 505 & 506, 5th Floor, Main OPD building, VMMC & Safdarjung Hospital, New Delhi 110029 **ECR/593/Inst/DL/2014/RR-25**
2	**Dr Raja Dhar** The Calcutta Medical Research Institute, 7/2 Diamond Harbour Road, Kolkata 700027, India	Institutional Ethics Committee, The Calcutta Medical Research Institute, 7/2 Diamond Harbour Road, Kolkata 700027, India **ECR/132/InstWB/2013/RR-24**
3	**Dr Srikanth K** Hindustan Hospital, 523/3 Nava India Road, Udaiyampalayam Coimbatore, Tamil Nadu - 641028	Institutional Human Ethics Committee, Hindustan Hospital, 523/3 Nava India Road, Udaiyampalayam Coimbatore, Tamil Nadu – 641028 **ECR/1376/Inst/TN/2020/RR-25**

4	**Dr. Gajendra Vikram Singh** Department of Respiratory Medicine, S N Medical College, Raja Mandi, Near Agra College, Agra Central Library, Moti Katra, Mantola, Agra Uttar Pradesh 282003 India	Institutional Ethics Committee, S N Medical College, Raja Mandi, Near Agra College, Agra Central Library, Moti Katra, Mantola, Agra Uttar Pradesh 282003 India. **ECR/1409/Inst/UP/2020/RR-25**
5	**Dr. Himanshu Pophale** Kothrud Hospital, Gadiya Estate, Opposite Hill View Park, Bhagya Chintamani Nagar, Guruganesh Nagar, Kothrud, Pune, Maharashtra 411038, India.	Central Independent Ethics Committee-CIEC Office no 413, 4th floor, onyx Business-5, Tilekar Nagar, Kondhwa BK, Pune 411048 Maharashatra. **ECR/390/Indt/MH/2024**
6	**Dr. Anand Kumar** Department of Respiratory Medicine, GSVM medical College, Swaroop Nagar Kanpur, 208002	Ethics Committee GSVM Medical College, room no 125, first floor, GSVM medical college, Swaroop Nagar, Kanpur 208002. **ECR/680/Inst/UP/2014/RR-20**
7	**Dr. Ashish Goyal** Orchid Speciality Hospital, L-Square, Porwal Road, Sr. No. 282/3/3, off Dhanori Jakat Naka, Lohgoan, Pune- 411047 Maharashatra	Orchid Speciality Hospital Ethics Committee, L-Square, Porwal Road, Sr. No. 282/3/3, off Dhanori Jakat Naka, Lohgoan, Pune- 411047 Maharashatra **ECR/1089/Inst/MH/2018/RR-21**
8	**Dr. C Prashanth** Princess Krishnarajamani Tuberculosis Hospital (PKTB) KRS Road, Kumbarakoppal, Gokulam, Mysuru, Karnataka - 570002	IEC-MMC and RI and Associated Hospital, Mysore Medical College and Research Institute Irwin Road Mysuru Mysuru (Mysore) Karnataka -570001 India **ECR/134/Inst/KA/2013/RR-24**
9	**Dr. Jaydip Deb** Nil Ratan Sircar Medical College & Hospital (NRSMC&H) 138, A.J.C Bose Road, Kolkata - 700014	Ethics Committee, NRS Medical College and Hospital, 138 A.J.C Bose Road, Kolkata, West Bengal – 700014 **ECR/609/Inst/WB/2014/RR-25**
10	**Dr. Jairaj Nair** Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, department of Respiratory Medicine, Sion, Mumbai, Maharashtra, India-400022	Institutional Ethics Committee Lokmanya Tilak Mumbai Maharashtra -400022 India Dr. Babasaheb Ambedkar Road, Sion (West) **ECR/266/Lokmanya/Inst/MH/2013/RR-24**
11	**Dr. Manish Jain** Maharaja Agrasen Super speciality Hospital Central Spine, Agrasen Aspatal Marg Sector 7, Vidhyadhar Nagar, Jaipur Rajasthan –302039 India	IEC, Maharaja Agrasen Hospital Maharaja, Maharaja Agrasen Super speciality Hospital Central Spine, Agrasen Aspatal Marg Sector 7, Vidhyadhar Nagar, Jaipur Rajasthan – 302039 India **ECR/1222/Inst/RJ/2019/RR-22**

12	**Dr. Rajkumar Nikalje** Punawala Multispecialty Hospital, Alpha Height Vishnu dev Nagar, Jambe road, Near Khandoba Mandir, Punawale, Pune 411033	Skinovate Independent Ethics Committee, Skinovate Laser And Cosmetic Surgery Center Office No.303, Royal Avenue, S.NO 18, Hissa No.11/6 Rahatani, Pimple Saudagar Pune Maharashtra - 411017 India **ECR/346/Indt/MH/2021**
13	**Dr. Ramakant Dixit** Jawaharlal Nehru Medical College, Kala Bagh, Ajmer, Rajasthan – 305001India	Institutional Ethics Committee, Jawahar Lal Nehru Medical College Kala Bagh, Ajmer, Rajasthan – 305001 **ECR/1156/Inst/RJ/2018/RR-22**
14	**Dr. Sandeep Kadian** Asian Institute of Medical Sciences, P/72 Milap Nagar, MIDC Dombivai, East 421203	Suraksha Ethics Committee Asian Institute of Medical Sciences Hospital Plot No.72, MIDC Milap Nagar Dombivali Thane Maharashtra – 421203 **ECR/644/Inst/MH/2014/RR-25**
15	**Dr. Sandeep Katiyar** Apollo Specialty Hospital Pvt. Ltd. 14/138, Chunni Ganj, Kanpur Nagar Uttar Pradesh - 208001 India	Apollo Specialty Hospitals Kanpur Ethics Committee, Apollo Specialty Hospital Pvt. Ltd. 14/138, Chunni Ganj, Kanpur Nagar Uttar Pradesh -208001 **ECR/1327/Inst/UP/2019/RR-24**
16	**Dr. Sanjay Khator** Shri Ambe Hospital and Research Institute, 8-9, Jai Karani Nagar Niwaru Road Jaipur Rajasthan - 302012 India	Shri Ambe Institutional Ethics Committee, Shri Ambe Hospital and Research Institute, 8-9, Jai Karani Nagar Niwaru Road Jaipur Rajasthan – 302012 **ECR/1557/Inst/RJ/2021**
17	**Dr. Sharad Tikkiwal** Department of Pulmonary Medicine, Asthma Bhawan, R-3, Sector-6, Vidyadhar Nagar, Jaipur 392039	Institutional Ethics Committee, Asthma Bhawan, R-3, Sector-6, Vidhyadhar Nagar Jaipur Jaipur, Rajasthan 302023. **ECR/750/Inst/RJ/2015/RR-21**
18	**Dr. Sumita Agrawal** Medipulse Hospital, E-4, MIA, Basni Phase -2, Opposite AIIMS, Jodhpur Rajasthan – 342005	Medipulse Hospital Institutional Ethics Committee, Medipulse Hospital, E-4, MIA, Basni Phase -2, Opposite AIIMS, Jodhpur Rajasthan – 342005 **ECR/1962/Inst/RJ/2024**
19	**Dr. Surendra Kumar** Clinical Research Unit, Near Medicine ICU & Maharaj MRI, Department of Medicine, S P Medical College, and A.G Hospital, Pawanpuri, Bikaner Rajasthan - 334003 India	Ethics Committee S P Medical College, S P Medical College, Bikaner Pawanpuri, Rajasthan – 334003 **ECR/27/SP/Inst/RJ/2013/RR-24**
20	**Dr. Vipul Khandelwal** Apex Hospitals Private Limited SP 4 and 6 Industrial Area, Malviya Nagar Jaipur Rajasthan - 302017 India	Institutional Ethics Committee, Apex Hospitals Private Limited SP 4 and 6 Industrial Area, Malviya Nagar Jaipur Rajasthan - 302017 India **ECR/380/Inst/RJ/2013/RR-24**

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2026.03.13 17:24:15 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

New Delhi